Cometriq for Medullary Thyroid Cancer

Cometriq (cabozantinib) is now FDA approved for the treatment of progressive metastatic medullary thyroid cancer. It is an oral chemotherapy involved in inhibiting multiple tyrosine kinases which are involved with cancer growth and spread.